PT-141, also known by its generic name bremelanotide and the brand name Vyleesi, is a melanocortin receptor agonist used for low sexual desire. It activates MC4 receptors in the central nervous system, which is mechanistically different from drugs like sildenafil (Viagra) that work on blood vessels in the genital tissue.<\/p>\n
The FDA approved bremelanotide in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only FDA-approved on-demand sexual desire medication for that indication. Off-label use in men exists but lacks the same regulatory pathway.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Bremelanotide is a synthetic analog of alpha-melanocyte stimulating hormone (alpha-MSH).<\/strong> It binds melanocortin receptors, with strongest activity at MC4R and weaker activity at MC3R, MC1R, and MC5R. MC4R activation in the hypothalamus is thought to modulate sexual desire pathways through dopamine signaling.<\/p>\n Quick Answer: FDA-approved as Vyleesi (2019) for HSDD in premenopausal women<\/p>\n This is a fundamentally different mechanism from PDE5 inhibitors like sildenafil and tadalafil. Those drugs work on the vasculature in genital tissue, enhancing the response to existing sexual stimulation but not creating desire itself. PT-141 acts upstream at the level of central nervous system desire signaling.<\/p>\n The clinical effect is that bremelanotide can produce subjective increases in sexual interest in patients who lack it. It does not increase genital blood flow on its own and is not an erection pill.<\/p>\n The RECONNECT trials (Kingsberg et al.<\/strong> 2019 Obstetrics and Gynecology) were the phase 3 program supporting approval. Two identical double-blind, placebo-controlled trials randomized over 1,200 premenopausal women with HSDD to either 1.75 mg subcutaneous bremelanotide or placebo, used as needed before anticipated sexual activity.<\/p>\n Bremelanotide produced statistically significant improvement in sexual desire scores (using the Female Sexual Function Index) and reduction in distress related to low desire. Effect size was modest, with about 25 percent of bremelanotide patients reporting meaningful improvement versus 17 percent on placebo.<\/p>\n The trials excluded postmenopausal women, women with relationship distress, and women with depression or medications affecting sexual function. So the population in which it was tested is narrower than how it’s sometimes prescribed off-label.<\/p>\n The most frequent adverse events in the RECONNECT trials were nausea (40 percent), flushing (20 percent), and headache (11 percent).<\/strong> Nausea is dose-dependent and tends to peak in the first hour after injection, fading over 4 to 6 hours. About 13 percent of patients in trials discontinued due to nausea.<\/p>\n A particular characteristic side effect is focal hyperpigmentation. Bremelanotide weakly activates MC1R, which controls melanin production. Repeated dosing can cause darkening of the face, gums, or breasts, particularly in people with darker skin tones. This is one reason the drug is recommended for occasional, not daily, use.<\/p>\n Transient blood pressure elevation is reported, typically 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after dose. The FDA label cautions against use in uncontrolled hypertension and cardiovascular disease.<\/p>\n The approved dose is 1.75 mg subcutaneously, administered 45 minutes before anticipated sexual activity.<\/strong> Effects last 8 to 16 hours. No more than one dose in 24 hours and no more than 8 doses per month.<\/p>\n The drug is supplied in a single-use autoinjector. Compounded versions of PT-141 are dosed by individual clinicians, often in the same 1.5 to 2 mg range, though some protocols use lower doses to mitigate nausea.<\/p>\n There is no daily or maintenance dosing schedule for bremelanotide. It is strictly on-demand.<\/p>\n Key Takeaway: Administered subcutaneously 45 minutes before sexual activity<\/p>\n Off-label, yes. There’s a phase 2 trial history of bremelanotide for erectile dysfunction in men (Diamond et al. 2006), which showed some efficacy in producing erections in response to sexual stimulation. Palatin Technologies (the developer) initially pursued ED as an indication but shifted to female HSDD because the regulatory pathway and unmet need were stronger.<\/p>\n Men using compounded PT-141 typically use doses of 1 to 2 mg subcutaneously, 45 minutes before anticipated activity. Reports suggest some men experience increased sexual desire and improved erections, with the same nausea and flushing side effects.<\/p>\n There is no FDA-approved indication for bremelanotide in men. Compounded use in men is a clinician decision and not supported by phase 3 data.<\/p>\n For erectile dysfunction in men, PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) remain first-line.<\/strong> They work through a clear mechanism (enhanced cGMP signaling in penile vasculature) and have strong phase 3 data. PT-141 is not a replacement.<\/p>\n For low desire in women, options include flibanserin (Addyi), which is taken daily and works through serotonergic mechanisms. The RECONNECT and BEGONIA trials of flibanserin showed similar modest effect sizes. Choice between flibanserin and bremelanotide depends on whether daily or on-demand dosing fits the patient’s life.<\/p>\n For men with low libido, the primary workup includes testosterone levels, depression screening, medication review (SSRIs, antihypertensives), and sleep evaluation. Testosterone replacement for hypogonadal men is the evidence-based approach. PT-141 is not the first-line.<\/p>\n Bremelanotide is contraindicated in uncontrolled hypertension and known cardiovascular disease.<\/strong> The transient blood pressure rise can be problematic in patients with poorly managed hypertension.<\/p>\n It’s not recommended in pregnancy or breastfeeding, and the FDA label warns against use during pregnancy.<\/p>\n The drug should not be combined with naltrexone or oral opioids because bremelanotide may reduce the effectiveness of naltrexone for opioid use disorder.<\/p>\n Bottom line: Distinct from sildenafil\/tadalafil, which are PDE5 inhibitors<\/p>\n Long-term safety data are limited. The on-demand dosing pattern with monthly use caps reduces cumulative exposure. The hyperpigmentation risk grows with cumulative dose. Annual blood pressure monitoring is standard for patients using it regularly.<\/p>\n Off-label combinations exist, but the FDA label for Vyleesi cautions against combination with antihypertensives and notes no formal interaction studies with PDE5 inhibitors. Any combination should be cleared with a prescribing clinician.<\/p>\n Effects begin around 30 to 60 minutes after subcutaneous injection. Peak effect is at 1 to 2 hours. The window of activity is roughly 8 to 16 hours.<\/p>\n MC4R activation in the brain stem area postrema can produce nausea, similar to how GLP-1 medications cause nausea through central pathways. The nausea is most pronounced on the first few doses and tends to attenuate with repeated use.<\/p>\n The phase 3 trials excluded patients with depression or those on antidepressants. Off-label use in patients with SSRI-induced sexual dysfunction has been reported in case series, but there is no controlled trial evidence specifically for this population.<\/p>\n GLP-1 medications can affect sexual function indirectly through weight loss and improved cardiovascular health. There is no direct interaction studied with bremelanotide. Patients on semaglutide or tirzepatide through programs like TrimRx who experience sexual dysfunction concerns should discuss them with the prescribing clinician, who can determine whether weight management alone improves things or whether a separate workup is warranted.<\/p>\n Yes, compounded bremelanotide is available through 503A pharmacies with a prescription. As with all compounded peptides, quality varies by pharmacy. Asking for a certificate of analysis and confirming USP-grade source material is the basic due diligence.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" PT-141, also known by its generic name bremelanotide and the brand name Vyleesi, is a melanocortin receptor agonist used for low sexual desire.<\/p>\n","protected":false},"author":11,"featured_media":91010,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"What Is PT-141 and How Does It Work?","_yoast_wpseo_metadesc":"PT-141, also known by its generic name bremelanotide and the brand name Vyleesi, is a melanocortin receptor agonist used for low sexual desire.","_yoast_wpseo_focuskw":"what pt","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-91011","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=91011"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91011\/revisions"}],"predecessor-version":[{"id":92057,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91011\/revisions\/92057"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/91010"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=91011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=91011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=91011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Does the Trial Data Show?<\/h2>\n
What Are the Common Side Effects?<\/h2>\n
How Is Bremelanotide Dosed?<\/h2>\n
Is PT-141 Used in Men?<\/h2>\n
How Does PT-141 Compare to Other Sexual Health Treatments?<\/h2>\n
What Are the Contraindications?<\/h2>\n
FAQ<\/h2>\n
Is PT-141 Safe for Long-term Use?<\/h3>\n
Can PT-141 Be Combined with PDE5 Inhibitors?<\/h3>\n
How Quickly Does PT-141 Work?<\/h3>\n
Why Does PT-141 Cause Nausea?<\/h3>\n
Does PT-141 Help with Depression-related Low Libido?<\/h3>\n
How Does This Fit with Weight Loss Medications Like TrimRx GLP-1s?<\/h3>\n
Can I Get PT-141 Through a Compounding Pharmacy?<\/h3>\n